



## Health Advisory: Make Evusheld Available To Eligible Patients

July 21, 2022

The purpose of this health advisory is to remind clinicians about the [availability of Evusheld](#) as **pre-exposure prophylaxis (PrEP)** for COVID-19 in certain adult and pediatric patients (12 years of age and older weighing at least 40 kg). **Providers are encouraged to reach out to all patients eligible for Evusheld to discuss risks and benefits and ensure access to this medication.** [Evusheld is authorized](#) for persons:

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND
- Who have [moderate to severe immune compromise](#) due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, or
- For whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s). *Evusheld contains polysorbate 80, which is in the Janssen COVID-19 Vaccine and is structurally similar to polyethylene glycol (PEG), an ingredient in the Pfizer-BioNTech and Moderna COVID-19 vaccines. Clinicians should consider consulting an allergist-immunologist prior to administering Evusheld to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to a COVID-19 vaccine.*

The authorized Evusheld initial dose is **300 mg of tixagevimab and 300 mg of cilgavimab** administered as two separate consecutive intramuscular (IM) injections. If ongoing protection is needed, a repeat dose of 300 mg of tixagevimab and 300 mg of cilgavimab should be administered **every 6 months**. Despite a decrease in neutralizing activity with currently circulating variants, pharmacokinetic modeling suggests that sufficient activity against these subvariants may be retained for six months.

Please also visit ACPHD's [Treatment webpage](#).

**For questions regarding the distribution of COVID-19 outpatient therapeutic products within ALCO,** please contact Cynthia Frankel, RN, Alameda County Therapeutics Distribution Lead at [cynthia.frankel@acgov.org](mailto:cynthia.frankel@acgov.org)

**For clinical questions about COVID-19 therapeutics,** please contact Arnie Spanjers, MD, Alameda County Public Health Department at [arnie.spanjers@acgov.org](mailto:arnie.spanjers@acgov.org)